AI Article Synopsis
- Relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations is challenging to treat, and gilteritinib is a powerful oral medication that can improve survival rates in these cases.
- A study involving 22 patients showed that a combination treatment of gilteritinib with hypomethylating agents and venetoclax (HMA-VEN-GILT) achieved a 77.3% overall response rate, with significant numbers of patients showing partial responses.
- Follow-up indicated promising outcomes, including a 6-month overall survival rate of 84% and a 29.4% relapse rate, suggesting that HMA-VEN-GILT can serve as an effective treatment strategy and bridge to stem cell
Article Abstract
Relapsed or refractory (R/R) acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutations remains a difficult and hard to treat entity. Gilteritinib is a potent oral FLT-3 inhibitor that improves overall survival in R/R AML, but studies are limited in combining gilteritinib with a hypomethylating agent and venetoclax treatment backbone (HMA-VEN-GILT). Here we report our experience with HMA-VEN-GILT for 22 R/R FLT3 AML patients. HMA-VEN-GILT yielded an ORR of 77.3% (17/22), CR 4.5% (1/22), CRi 13.6% (3/22), MLFS 59.1% (13/22). Median follow-up was 10.4 months with a relapse rate of 29.4% (5/17), median time to relapse of 69 days (range 35-298 days), 6-month overall survival of 84%, and median OS of 10.1 months. Additionally, 36.4% (8/22) of patients proceeded to hematopoietic stem cell transplant. In conclusion, HMA-VEN-GILT for the treatment of R/R FLT3 AML is feasible and can be used as a bridge to allogeneic transplantation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2023.2292473 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!